Superpower Health Review: What Real Customer Outcomes Tell Women Before They Subscribe

What Is Superpower and How Does Its Model Work?

Superpower markets itself as a concierge-style preventive health membership: you pay a subscription fee, get a large laboratory panel drawn at a partner lab, and then have access to telehealth clinicians who can review results and write prescriptions. The pitch is that conventional primary care rarely orders enough tests and rarely spends enough time discussing optimization. For women who have spent years being told their labs are "normal" while feeling anything but, that pitch lands.

The model is not unique. Companies like Function Health, Levels, and Parsley Health operate in overlapping territory. What differentiates Superpower's marketing is an emphasis on direct Rx access, including medications that primary care physicians sometimes under-prescribe, such as metformin for insulin resistance, thyroid optimization, or low-dose naltrexone.

How the Subscription Works Step by Step

After paying the membership fee, you schedule a blood draw at a Quest or LabCorp partner location. Results are returned through the Superpower app or portal. A clinician reviews them asynchronously, or you book a synchronous video visit. If a prescription is appropriate, it is sent electronically to a pharmacy of your choice. Ongoing messaging access is included in the base plan.

What the Membership Fee Actually Covers

The base subscription typically covers the lab panel, clinician review, and messaging. Prescriptions themselves are not included in the fee; you pay your pharmacy's retail or insurance price. Some medications commonly discussed in preventive contexts, such as GLP-1 receptor agonists, carry costs of $900 to over $1,300 per month without insurance, which dramatically changes the total cost calculus for any woman considering this service.

The Lab Panel: What Women Actually Get Tested

The comprehensiveness of the lab panel is Superpower's clearest selling point. Conventional insurance-covered annual physicals typically include a basic metabolic panel, CBC, and lipids. Superpower's panel reportedly spans 100-plus biomarkers, which sounds impressive until you examine which markers matter most for women at different life stages.

Markers That Are Genuinely Useful for Women

For a woman in her reproductive years with suspected PCOS, the relevant markers are free and total testosterone, LH, FSH, DHEA-S, fasting insulin, and sex hormone-binding globulin. PCOS diagnostic criteria from the Endocrine Society require biochemical hyperandrogenism alongside clinical features, making a panel that includes free testosterone genuinely useful rather than cosmetic.

For a perimenopausal woman, FSH above 25 IU/L on two draws at least six weeks apart, combined with irregular cycles, supports the perimenopausal diagnosis per The Menopause Society's 2023 position statement. Estradiol levels fluctuate too much day-to-day to be diagnostic alone, but tracking trends can be clinically informative.

Thyroid panels that go beyond TSH to include free T4 and free T3 are genuinely more informative for women, who experience autoimmune thyroid disease at five to eight times the rate of men. Postpartum thyroiditis affects approximately 5 to 10 percent of women in the year following delivery and is routinely missed without repeat thyroid testing.

Markers That Are Less Clinically Actionable

A 100-biomarker panel creates a statistical certainty of false positives. If a lab uses a 95th percentile reference range, approximately five out of every 100 values will fall outside normal in a completely healthy person purely by chance. For women, this can generate anxiety around results that require no intervention. Superpower's clinical team would need to contextualize this explicitly, and from publicly available reviews, that contextualization is inconsistent.

What Superpower Prescribes and Whether It Is Appropriate for Women

This is where the analysis requires the most care. Superpower's telehealth clinicians can prescribe a range of medications depending on the state you live in and the clinician's scope of practice.

Metformin for Metabolic Health and PCOS

Metformin is the most commonly prescribed medication for insulin resistance in women with PCOS. The American College of Obstetricians and Gynecologists' 2023 PCOS guidance supports metformin use for metabolic management in PCOS, particularly in women who do not respond adequately to lifestyle intervention. Doses typically range from 500 mg once daily titrating to 1,500 to 2,000 mg daily in divided doses.

For women who are trying to conceive, metformin is used adjunctively in some PCOS protocols, though evidence for improving live birth rates as monotherapy is modest compared to letrozole. A Superpower clinician prescribing metformin without asking about conception plans would be a gap worth probing during your intake visit.

Thyroid Optimization Beyond TSH Normalization

Some concierge and direct-to-consumer platforms prescribe T3-containing thyroid preparations, such as liothyronine or desiccated thyroid, when TSH sits in the low-normal range and a patient reports persistent symptoms. The American Thyroid Association's 2017 guidelines note insufficient evidence to recommend combination T4/T3 therapy as routine first-line treatment, though they acknowledge it may be appropriate in select patients who fail levothyroxine alone.

Women should know that TSH targets shift during pregnancy. The American Thyroid Association recommends TSH below 2.5 mIU/L in the first trimester for women with known hypothyroidism. A Superpower clinician managing your thyroid should be asking about pregnancy plans at every prescription renewal.

Low-Dose Naltrexone

Low-dose naltrexone (LDN), typically 1.5 to 4.5 mg nightly, is prescribed off-label for conditions including fibromyalgia, autoimmune disease, and fatigue. Evidence remains preliminary: a 2018 Cochrane-adjacent systematic review found limited high-quality randomized controlled trials. Women considering LDN through Superpower should understand they are entering experimental-evidence territory. LDN is not safe during pregnancy and must be discontinued before conception; it can precipitate opioid withdrawal in women on opioid therapy.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide prescribing through concierge platforms has expanded rapidly. ACOG does not recommend GLP-1 receptor agonists during pregnancy; animal studies show fetal harm, and these drugs should be discontinued at least two months before planned conception. Women of reproductive age prescribed semaglutide or tirzepatide should use reliable contraception. GLP-1 agonists may reduce the bioavailability of oral contraceptives by altering gastric emptying, per the FDA prescribing information for semaglutide, so barrier backup or non-oral contraception methods deserve discussion.

Pregnancy, Lactation, and Contraception: What Superpower Does Not Address Well

This section warrants plain language. Superpower is not a prenatal care platform. It has no published protocol for pregnant or lactating women. If you are pregnant, trying to conceive, or breastfeeding, the following applies to every medication category the platform prescribes.

Metformin: Compatible with use in pregnancy for gestational diabetes management under physician supervision, but self-managed titration without obstetric oversight is not appropriate. Metformin transfers into breast milk at low levels; evidence to date suggests it is likely compatible with breastfeeding but formal lactation guidance recommends coordination with a prescribing OB-GYN.

Levothyroxine and liothyronine: Levothyroxine is safe and necessary in pregnancy. Liothyronine (T3) has very limited human pregnancy safety data. If your Superpower clinician has you on desiccated thyroid or liothyronine and you become pregnant, transfer of care to a maternal-fetal medicine or endocrinology specialist is strongly advised.

Low-dose naltrexone: Contraindicated in pregnancy. Must be stopped before attempting conception. There are no adequate human data on fetal risk.

GLP-1 agonists (semaglutide, tirzepatide): Contraindicated in pregnancy. Animal data show fetal harm. FDA labeling advises discontinuing at least two months before planned pregnancy given the long half-life. Women of reproductive age on these medications need reliable contraception and must have a clear plan for discontinuation if pregnancy is desired.

DHEA supplements: Sometimes recommended in women with low DHEA-S levels. DHEA is contraindicated in pregnancy; it is not appropriate during lactation due to potential androgenic effects on a breastfed infant.

The honest assessment: Superpower's telehealth infrastructure does not appear to systematically screen for pregnancy status or contraception use at the time of prescribing based on publicly available information about their model. Women of reproductive age should raise this proactively in every clinical visit.

Superpower vs. Alternatives: How Does It Stack Up for Women?

The following framework is original to WomanRx and not reproduced from any competitor or brand material. It is designed to help women evaluate direct-to-consumer preventive health subscriptions across dimensions that matter specifically to female physiology and life stage.

| Criterion | Superpower | Function Health | Parsley Health | Your OB-GYN + Primary Care | |---|---|---|---|---| | Hormone panel depth | High | High | Moderate | Variable | | PCOS-specific protocol | Not specified | Not specified | Yes | Yes (ACOG-guided) | | Perimenopausal support | Not specified | Not specified | Yes | Yes (NAMS-guided) | | Telehealth Rx access | Yes | No Rx | Yes | Yes | | Pregnancy/lactation safety screening | Not documented | N/A | Better documented | Strongest | | Evidence-based prescribing guidelines | Variable | N/A | Moderate | Highest | | Cost per year (approx.) | $999+ | $499-$999 | $1,500-$2,000 | Covered by insurance (copays vary) | | Postpartum/lactation care | Not offered | Not offered | Limited | Full scope |

For women in perimenopause specifically, The Menopause Society (NAMS) has a Menopause Society Certified Menopause Practitioner (MSCP) directory that connects you with clinicians whose entire scope is your hormonal transition. A NAMS-certified provider typically has far deeper expertise in managing perimenopausal symptoms than a general preventive health platform.

For women with PCOS, reproductive endocrinologists and OB-GYNs who follow ACOG's 2023 PCOS clinical practice guideline will have more structured, evidence-grounded protocols than a concierge subscription service.

Is Superpower Legit? A Critical Look at Evidence and Regulation

Superpower is a legally operating telehealth company. Its prescribers are licensed clinicians subject to state medical board oversight. The platform itself is not a scam in the conventional sense.

The more precise question is whether its clinical protocols are evidence-based, and here the honest answer is: partially. Preventive medicine as a field supports comprehensive metabolic and hormonal screening for women whose conventional care is inadequate. A 2022 analysis in JAMA Internal Medicine found that adult preventive care recommendations are chronically under-delivered in primary care settings, with women receiving fewer metabolic screenings than men despite higher rates of autoimmune and thyroid disease.

Where Superpower deserves scrutiny is the optimization framing applied to results that sit within normal reference ranges. Prescribing metformin, thyroid medication, or testosterone to women based on "suboptimal" values within the normal range, rather than documented pathology, moves into territory where the evidence is thin and the risk of harm, though low, is real.

No Published Outcomes Data

As of this review, Superpower has published no peer-reviewed outcomes data from its patient population. There are no published randomized trials. There is no prospective cohort study showing that Superpower members achieve better cardiovascular, metabolic, or hormonal outcomes than matched controls receiving standard care. This is consistent with most DTC health platforms, but it is a genuine evidence gap women should factor into their decision. This mirrors a wider problem: women have been historically under-represented in preventive medicine trials, making it harder to extrapolate what "optimal" biomarker ranges mean specifically in female physiology.

Customer Reviews: What Real Women Report

Aggregated from public review platforms and forums, women's experiences with Superpower cluster around a few consistent themes. Positive reports describe the relief of finally getting a comprehensive panel that catches a thyroid abnormality, elevated fasting insulin, or low ferritin that their GP missed. Negative reports describe inconsistent clinician follow-through, prescriptions written without adequate intake questions, and difficulty reaching a clinician when results required urgent clarification. A specific frustration among women: the panels do not automatically include markers for postpartum thyroiditis screening or cycle-phase-specific hormone testing, meaning a single blood draw may not capture hormonally cycling women accurately.

Who Superpower Is Right For, and Who Should Look Elsewhere

Women Who May Benefit

Superpower may be a reasonable option for a woman who is in her 30s or 40s, is not pregnant or planning pregnancy in the near term, has had repeated dismissals from conventional primary care despite symptoms consistent with thyroid dysfunction, insulin resistance, or hormonal imbalance, and who has the income or health savings account funds to absorb the cost without financial strain. The comprehensive panel alone, if it catches an actionable finding like subclinical hypothyroidism or prediabetes, may justify the membership cost in a single year.

Women with established PCOS who have already been evaluated by an endocrinologist and simply want closer metabolic monitoring might find the subscription useful as a tracking tool, provided they maintain their specialist relationship.

Women Who Should Look Elsewhere

Women who are pregnant, postpartum, or actively trying to conceive should not use Superpower as their primary clinical home for hormonal or metabolic management. The platform is not equipped to manage pregnancy-specific lab interpretation, dose adjustments in pregnancy, or lactation safety.

Women in active perimenopause with complex symptoms, including vasomotor symptoms, genitourinary syndrome of menopause (GSM), or sexual health changes, are better served by a NAMS-certified menopause practitioner who has dedicated training in hormone therapy protocols, including the individualized risk-benefit analysis required per the 2023 NAMS hormone therapy position statement.

Women with a personal or family history of hormone-sensitive cancers, clotting disorders, or cardiovascular disease need specialist oversight, not a subscription platform.

How Much Does Superpower Cost, and Is It Worth It?

The membership runs approximately $999 per year or $99 per month as of early 2025, though pricing has varied by launch offer and geography. This does not include the cost of prescriptions. Fasting lab draws require time off work and travel to a partner location. The platform does not accept insurance for the membership fee, though prescriptions may be covered by your plan.

For context, a comprehensive hormone and metabolic panel ordered through a conventional physician and billed to insurance would likely cost you $0 to $150 in copays, depending on your plan, though getting that panel ordered in the first place is the documented barrier. A 2019 study in Health Affairs found that women are significantly more likely than men to have their symptoms attributed to anxiety or lifestyle factors rather than receiving a diagnostic workup, which is a real and documented problem that platforms like Superpower are attempting to address.

The honest math: if you are paying $999 per year and one actionable finding prevents a downstream complication, or if months of fatigue are finally explained by low free T3, the value is real. If you are paying $999 per year for reassurance on labs that a primary care physician would have ordered anyway, the value is harder to defend.